ReviewMolecular biology reports2026
Multi-omics approaches to parkinsonism: genomic, proteomic, and non-coding RNA perspectives.
Review in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Special Issue "Molecular Advances in Biomarkers of Central Nervous System Diseases and Disorders".International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Parkinson's disease (PD) is a progressive neurodegenerative disorder with significant variability associated with substantial loss of dopaminergic neurons in the substantia nigra. Currently, there are limited opportunities for intervention. There is a lack of reliable biomarkers to identify patients with PD, which poses a challenge for clinicians. In this review, recent advances in PD biomarker research, including genomic, epigenomic, proteomic, and non-coding RNA, will be highlighted, with particular emphasis on integrating omics for precision medicine. In addition, the current understanding of PD pathogenesis will be covered, including the root cause of familial and sporadic PD, as well as other significant contributing pathogenic events such as the formation of α-synuclein aggregates, mitochondrial dysfunction, autophagy, oxidative stress, and neuroinflammation. Recent progress in proteomic biomarkers, including cerebrospinal fluid and blood biomarkers such as α-synuclein, Neurofilament-Light-Chain, and dopamine-associated proteomics, will be reviewed for their utility. Merging evidence on non-coding RNAs, including microRNAs, long non-coding RNAs, circular RNAs, and piRNAs, further supports the notion of non-coding RNAs' regulatory functions in PD pathogenesis and their potential as non-invasive biomarkers. Lastly, strategies that integrate multi-omics data through systems biology, machine learning, and artificial intelligence are presented as viable approaches to support improved patient diagnosis and stratification, as well as the identification of new drug targets for PD. However, challenges related to heterogeneity, reproducibility, and clinical translation continue to limit the implementation of multi-omics biomarkers in PD. Overall, integrative multi-omics approaches combined with advanced computational strategies may provide a more comprehensive framework for early diagnosis, patient stratification, and the development of disease-modifying therapies in PD.
Indexed as
Identifiers
42377625What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.